Cambridge Healthtech Institute’s 2nd Annual
Immuno-Oncology Investing & Partnering Forum
( がん免疫療法投資提携フォーラム )
7:45 Registration and Morning Coffee
8:25 Organizer’s Welcome Remarks
8:30 PLENARY KEYNOTE SESSION
PANEL DISCUSSION: Partnering and Licensing in Immuno-Oncology
Big pharma and biotech are under pressure to compete in the booming Immuno-Oncology market and to capitalize on new technologies and innovations to bring next-generation immunotherapies to the patients. This insider panel will share what they look for in a partner or investment, and discuss opportunities for collaboration or in-licensing of novel immunotherapies, IO targets or biomarkers, and potential combination therapies.
Jeroen H. Blokhuis, PhD
Director, Business Development, Partnerships, Parker Institute for Cancer Immunotherapy
Michael Woo, MBA
Head, Search & Evaluation, Immuno-Oncology, Business Development & Licensing, Novartis Institutes for BioMedical Research, Inc.
Kathryn McCabe, PhD
Senior Director, Business Development, Emerging Technology and Innovation, Eli Lilly and Company
Scott M. DeWire, PhD
Global Head, Business Development and Licensing, Cancer Immunology, Boehringer Ingelheim Pharmaceuticals, Inc.
Philip Arlen, MD
President & CEO, Precision Biologics
Stephen Doberstein, PhD
Senior Vice President, R&D and Chief Research and Development Officer, Nektar Therapeutics
9:30 Networking Coffee Break in the Exhibit Hall
10:15 PANEL DISCUSSION: Corporate Venture Capital for Oncology and Immuno-Oncology
In this panel discussion, we will hear from venture capitalists representing arms of pharma companies. What are the benefits of working with a corporate venture capital entity vs private or angel? What are pharma and biotech venture capitalists looking for in a startup company?
Panelist: John Gustofson, Managing Director, AbbVie Ventures
11:15 Targets and Biomarkers
With record numbers of immunotherapies in active development, the importance of targets such as the tumor microenvironment is becoming clear. How do you determine what to target? Once you have a target, how do you deliver therapies effectively? This session will preview next-generation products and companies.
Session Speakers: Michael Aberman, MD, President, CEO, Quentis Therapeutics, Inc.
Christopher Thanos, PhD, CEO, Cofounder, Actym Therapeutics, Inc.
Anton Neschadim, PhD, MBA, President & CEO, Immunobiochem Corporation
12:15 Enjoy Lunch on Your Own
1:30 PANEL DISCUSSION: Investing in Immuno-Oncology
In this panel discussion, private, public and strategic investors will discuss their investment strategies. Potential topics of discussion include: What does it take to get an immuno-oncology company funded? What are the benefits and risks of business models in devices, pharmaceuticals, diagnostics and information technology? What are today’s deal terms and valuations? What are the best exit strategies?
Panelists: Stephen Curtis, PhD, Managing Director, MPM Capital
Alexis Ji, PhD, Partner, Illumina Ventures
Shaan C. Gandhi, MD, DPhil, Principal, Longwood Fund
2:30 Networking Refreshment Break
3:15 Novel Therapeutics and Diagnostics for Cancer Immunotherapy
In this session, we will hear from companies on the cutting edge. Novel drugs are being developed and commercialized, and new pathways for cancer diagnostics are being discovered and targeted. Innovative technology is yielding benefits in development of diagnostics and treatments. Hear from leading companies on their approaches.
Session Speakers: Stephen J. Russell, MD, PhD, CEO, Vyriad, Inc.
Charlene Liao, PhD, President and CEO, Immune-Onc Therapeutics
4:15 Start-Up Showcase
The Immuno-Oncology Investing & Partnering Forum’s 2nd Annual Start-Up Showcase offers the stage to young immuno-oncology companies to pitch their drug, device, diagnostic, or software to an audience of investors, CEOs, and executives in the field.
5:15 Close of Immuno-Oncology Investing & Partnering Forum